Navigation Links
Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
Date:6/26/2010

ORLANDO, Fla., June 26 /PRNewswire/ -- Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose (PPG).(1,2)  Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 (DPP-4) inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes. The linagliptin data are being presented this week at the 70th Annual American Diabetes Association (ADA) Scientific Sessions in Orlando, Fla.

In the Phase III studies, statistically significant placebo-adjusted changes in HbA1c were observed with linagliptin (5 mg) monotherapy versus placebo (-0.69 percent, p<0.0001)(1) and when used in combination with other commonly-used oral anti-diabetic drugs, including metformin (-0.64 percent, p<0.0001),(2) metformin plus a sulfonylurea (-0.62 percent, p<0.0001),(3) and as initial combination with pioglitazone (-0.51 percent, p<0.0001).(4) Linagliptin therapy also resulted in improvements in beta-cell function.(1) Declining beta-cell function is believed to be a key factor driving the progression of type 2 diabetes.(5)

"It is imperative that blood sugar levels in people with type 2 diabetes are adequately controlled," said Dr. Giora Davidai, executive director & medical leader, medical affairs, cardiovascular & metabolic medicine, Boehringer Ingelheim Pharmaceuticals, Inc. "Uncontrolled blood sugar puts type 2 diabetes patients at a higher risk of developing serious complications like renal impairment and cardiovascular disease, which are very common in patients with type 2 diabetes."


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
2. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
3. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
4. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Boehringer Ingelheim Unveils Diabetes Pipeline
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
10. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
11. MediPurpose® Announces U.S. Distribution Agreement With Pharmaplast, Egyptian Advanced Wound Care OEM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and HOUSTON, TX , Feb. ... "Company") (TSX-V: EPI) and Bloom Burton & Co. Ltd. ... voluntary contractual lock-up (the "Lock-Up") 2,353,130 common shares of ... Shares originally subject to the Lock-Up. Of the Common ... free trading immediately upon release from the Lock-Up while ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma Corp. ... biopharmaceutical company developing therapeutic products for rare diseases, ... the European Organisation for Rare Diseases™ (EURORDIS™), The ... in observing Rare Disease Day. On ... organizations, industry, and other participants conduct special events ...
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx,Incorporated ... its,randomized, blinded, placebo-controlled phase 2 clinical trials ... rheumatoid,arthritis (RA) will be featured at the ... Rheumatology meeting, June,13-16, 2007 in Barcelona, Spain., ...
... study results confused the public about the,need and ... /PRNewswire/ -- The onslaught of,anti-stent news reports over ... that angioplasty doesn't work and its use should,decrease. ... their cardiologists about the benefits of stenting. , ...
Cached Medicine Technology:Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 2Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 3To Stent or Not: Is That the Question? 2
(Date:2/28/2015)... (PRWEB) March 01, 2015 Heart diseases ... that 10 percent of urban adult population and 5 ... of heart diseases and 20-30 percent of them require ... heart ailments and coronary vascular diseases (CVD). , A ... a new market research report titled “Indian Coronary Stent ...
(Date:2/28/2015)... 2015 The Heart Fit Clinic started ... of the machine. The Heart Fit Clinic is also ... a franchise model. The goal is to scale the ... disease. To buy External Counterpulsation machines can ... individuals through this process and achieve the desired results. ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently ... limits. They stated that in many cases, missing an important ... it. Many a time, delays in making an injury claim ... law. As a result, experts at Jiwa Law Corporation suggest ... personal injury lawyer in order to know more about their ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation ... International Symposium on Malignant Mesothelioma on Monday, March 2. ... Regency Bethesda in Bethesda, Maryland. The following award recipients ... to the mission to cure mesothelioma. , The Klaus ... to Miriam Ratner. Miriam runs the Meso Foundation’s monthly ...
(Date:2/28/2015)... Orlando, FL (PRWEB) February 28, 2015 ... community organization has sponsored visitor health insurance programs for ... 25 years. Most Indian elderly parents traveling to the ... conditions such as diabetes and blood pressure. These diseases ... do not even list them as medical conditions. There ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3
... urinate, affects the quality of life of many women. ... can tolerate oral medications and may benefit from other therapies. ... is conducting a study to compare the effect of two ... trying other treatments. Patients are currently being enrolled in ...
... February 29, 2012 A new method for creating ... Institute of New York University (NYU-Poly), promises to greatly ... heart disorders and Alzheimer,s disease, as well as aid ... , In addition, applied differently, this same development could ...
... new way of measuring the potential success rate of an ... in vitro fertilisation (IVF). According to the findings published ... fluid within a woman,s ovaries that surrounds the egg or ... embryo is more likely to lead to pregnancy. "We ...
... TUESDAY, Feb. 28 (HealthDay News) -- Taking the hallucinogen ecstasy ... lead to poorer motor control in infants, a new study ... history before and during pregnancy. The women were taking part ... which looks at recreational drug use among pregnant women. Most ...
... elderly cancer patients are evolving as more of the population ... To address these issues and others, national thought leaders ... the Kimmel Cancer Center at Jefferson (KCC) in ... an overview of the latest advances in the understanding and ...
... all deaths in the United States are linked to behavioral ... Despite these causal links, of the $2 trillion spent annually ... that is devoted to addressing behavioral and social risk factors. ... behavioral and social sciences with a new $500,000 grant from ...
Cached Medicine News:Health News:Women & Infants studying therapies to relieve urinary urge incontinence 2Health News:Nanofiber breakthrough holds promise for medicine and microprocessors 2Health News:New test can better predict successful IVF embryos, scientists say 2Health News:Ecstasy Use During Pregnancy May Harm Fetus: Study 2Health News:A new battlefront: Symposium at Jefferson's Kimmel Cancer Center to tackle geriatric oncology 2Health News:A new battlefront: Symposium at Jefferson's Kimmel Cancer Center to tackle geriatric oncology 3Health News:Training grant targets behavioral and social factors linked to health 2Health News:Training grant targets behavioral and social factors linked to health 3
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: